---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-100771"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T21:19:03.369814+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Teva realigns reporting segments; Canada moved to International Markets from North America

## Summary
- Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.
- Recast 2023 and 2022 segment data shows US segment revenue $7,731M (2023) and segment profit $2,394M.
- Canada 2023 revenue $393M, down 12.5% from $449M in 2022, included in International Markets.
- No impact on previously reported consolidated financial statements; prior periods restated for comparability.

## SEC filing metadata
- accession: 0001193125-24-100771
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/0001193125-24-100771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/d800395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-100771
- JSON: https://secwatch.observer/filing/0001193125-24-100771.json
- Plain text: https://secwatch.observer/filing/0001193125-24-100771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.